CRISPR Therapeutics AG (STU:1CG) Additional Paid-In Capital : €2,943.2 Mil(As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is CRISPR Therapeutics AG Additional Paid-In Capital?

CRISPR Therapeutics AG's quarterly additional paid-in capital declined from Sep. 2023 (€2,643.5 Mil) to Dec. 2023 (€2,639.3 Mil) but then increased from Dec. 2023 (€2,639.3 Mil) to Mar. 2024 (€2,943.2 Mil).

CRISPR Therapeutics AG's annual additional paid-in capital increased from Dec. 2021 (€2,299.3 Mil) to Dec. 2022 (€2,581.7 Mil) and increased from Dec. 2022 (€2,581.7 Mil) to Dec. 2023 (€2,639.3 Mil).

CRISPR Therapeutics AG Additional Paid-In Capital Historical Data

The historical data trend for CRISPR Therapeutics AG's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CRISPR Therapeutics AG Additional Paid-In Capital Chart

CRISPR Therapeutics AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

1,046.11

1,837.73

2,299.33

2,581.69

2,639.27

CRISPR Therapeutics AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															2,578.82	2,583.87	2,643.49	2,639.27	2,943.25

CRISPR Therapeutics AG Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

CRISPR Therapeutics AG Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of CRISPR Therapeutics AG's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

CRISPR Therapeutics AG (STU:1CG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (STU:1CG) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

CRSP:USA CRSP:Mexico

Address

Baarerstrasse 14, Zug, CHE, CH-6300

Website

https://www.crisprtx.com

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

CRISPR Therapeutics AG (STU:1CG) Headlines

No Headlines